加速超分割放疗联合化疗治疗局限期小细胞肺癌的疗效分析  

Clinical effect of accelerated hyperfractionation radiotherapy combined with chemotherapy on limited small cell lung cancer

作　　者：温林春[1] 尤传文[1] 陆锡燕 陈建章[1] 

机构地区：[1]南京鼓楼医院集团宿迁市人民医院肿瘤科,江苏宿迁223800

出　　处：《临床肺科杂志》2012年第8期1460-1462,共3页Journal of Clinical Pulmonary Medicine

摘　　要：目的探讨加速超分割胸腔放疗联合EP方案治疗局限期小细胞肺癌的疗效及安全性。方法共72例局限期小细胞肺癌随机分为加速超分割组和常规分割组,其中加速超分割组放疗1.5 Gy/次,2次/日,间隔6小时,总量45Gy;常规分割组1.8～2 Gy/次,1次/日,总量50 Gy。两组全部采用EP方案化疗4～6周期。结果加速超分割组与常规分割组的有效率分别为82.8%和59.4%(P<0.05),加速超分割组与常规分割组的1年、2年和3年生存率分别为90.7%vs 83.1%、55.2%vs43.8%和25.4%vs 17.6%(P<0.05)。主要毒性反应为白细胞减少和放射性食管炎,超分割组的白细胞减少与放射性食管炎较常规分割组有所升高(P<0.05),但均可耐受。结论加速超分割放疗联合EP方案化疗提高了局限期小细胞肺癌的疗效,同时增加了骨髓抑制、放射性食管炎等急性放射性损伤,但是毒性反应可以耐受,值得进一步推广应用。Objective To explore the efficacy and safety of accelerated hyperfractionation radiotherapy combined with EP regimen on limited small cell lung cancer. Methods 72 patients were randomized into two groups ： 35 patients in accelerated hyperfractionation radiotherapy （HART） group, 37 patients in conventional fractionation radiotherapy （CFRT） group. Results The total effective rate（ PR ＋ CR） in HART group and in CFRT group were 82. 8% and 59. 4%. The 1,2, and 3 year survival rates in HART and CFRT were 90. 7% vs 83. 1% ,55.2% vs 43.8% and 25.4% vs 17.6% （ P 〈 0. 05 ）. The main adverse events were leukopenia and radiation esophagitis, which were significantly higher in HART group than those in CFRT group （ P 〈 0. 05 ）, but they could be tolerated. Conclusions This study suggests that EP regimen combined accelerated hyperfractionation radiotherapy was more effective and well tolerated. It should be further studied.

关 键 词：小细胞肺癌 超分割放射治疗 化疗 联合治疗 疗效 

分 类 号：R734.2[医药卫生—肿瘤]